Millennium Pharmaceuticals, Inc. will receive a $10 million payment from Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) based on sales milestones reached for Velcade for Injection in territories outside the U.S. “This milestone payment reflects the continued worldwide growth of Velcade, a market-leader in relapsed, refractory multiple myeloma, with more than 33,000 patients treated globally,” said Marsha Fanucci, chief financial officer and ...